Disclosure: We earn commissions on purchases made through our links. This never influences our scores. Editorial policy
Lutein + Zeaxanthin
Lutein and zeaxanthin are two of the only carotenoids that accumulate in the retina, where they form the macular pigment that filters short-wavelength light and quenches oxidative damage to photoreceptors.
- Evidence
- Likely Effective
- Category
- Vitamins & Minerals
- Best form
- FloraGLO Lutein (Kemin) - free lutein, the form used in AREDS2 and most positive RCTs; the dominant clinical-grade ingredient on the US market
- Effective dose
- 10mg lutein + 2mg zeaxanthin daily (AREDS2 dose)
- Lab tested
- 4 of 8 products
- Category
- Vitamins & Minerals
- Best form
- FloraGLO Lutein (Kemin) - free lutein, the form used in AREDS2 and most positive RCTs; the dominant clinical-grade ingredient on the US market
- Effective dose
- 10mg lutein + 2mg zeaxanthin daily (AREDS2 dose)
- Lab tested
- 4 of 8 products
Key takeaways
- →10mg lutein + 2mg zeaxanthin daily is the AREDS2 trial-validated dose; the full AREDS2 multi-ingredient formula (with zinc, copper, vitamins C and E) is what the trial actually tested for AMD.
- →AMD benefit is real but targeted: it is strongest in older adults with intermediate AMD or low dietary lutein, not in healthy younger adults as primary prevention.
- →FloraGLO (Kemin) and Lutemax 2020 (OmniActive) are the two standardized forms with their own clinical trial portfolios; generic lutein is the same molecule but quality varies more.
- →Visual performance and contrast/glare benefits in healthy adults are better-supported than the typical 'blue light' marketing makes obvious; expect 3-6 months before noticing changes.
- →Cognitive benefits in older adults are an early but replicating signal at 10-12mg lutein + 2mg zeaxanthin daily.
What Is Lutein + Zeaxanthin?
Lutein and zeaxanthin are two of the only carotenoids that accumulate in the retina, where they form the macular pigment that filters short-wavelength light and quenches oxidative damage to photoreceptors. The evidence base for supplementation is unusually strong for a supplement category, but it is also more nuanced than the marketing implies, and the strongest claims are not always the ones consumers expect.
The canonical trial is AREDS2 (Age-Related Eye Disease Study 2, n=4,203, JAMA 2013, PMID 23644932). In the primary intention-to-treat analysis, adding 10mg lutein + 2mg zeaxanthin to the AREDS formula did NOT significantly reduce overall progression to advanced AMD versus placebo. Where lutein/zeaxanthin showed a meaningful benefit was in two specific places: as a direct replacement for beta-carotene (lutein/zeaxanthin produced a 15-18% lower risk of late AMD vs. the beta-carotene arm), and in the subgroup with the lowest dietary lutein/zeaxanthin intake at baseline. The 10-year AREDS2 follow-up (Chew 2022, PMID 35653117) confirmed roughly a 9% reduction in late AMD progression with lutein/zeaxanthin and a 15% advantage over beta-carotene. So the AMD story is real, but it is targeted: it is strongest in higher-risk older adults with intermediate or large drusen and low dietary carotenoid intake, and weakest as primary prevention in healthy younger adults.
Visual performance in non-AMD adults is where the evidence has been surprisingly consistent. The Stringham/Hammond group at the University of Georgia has run a series of placebo-controlled trials in young, healthy adults showing that 10-20mg lutein plus 2-4mg total zeaxanthin daily for 6-12 months meaningfully improves contrast sensitivity, disability glare thresholds, and photostress recovery time (Stringham 2016, PMID 27857944). In a 6-month RCT specifically in heavy screen users at 24mg/day macular carotenoids, the same group reported improvements in MPOD, sleep quality, eye strain, and headache frequency (Stringham 2017, PMID 28661438). Bovier 2014 (PMID 25251377) showed that supplementation increased critical flicker fusion thresholds and visual motor reaction time by roughly 10-12% in young healthy subjects. The screen-time and contrast story has more real trial support than the typical "blue light" marketing suggests, though sample sizes are modest.
The cognitive evidence is the most preliminary but is replicating. Hammond/Renzi-Hammond 2017 (PMID 28824416, n=51 community-dwelling older adults, 12mg lutein + 2mg zeaxanthin daily for 12 months) found significant improvements in complex attention and cognitive flexibility, with a memory benefit in male participants. Lindbergh 2017 (Journal of the International Neuropsychological Society) reported the same trial cohort showed better brain activation patterns on functional MRI tasks. The mechanism is plausible: lutein concentrates in cortical regions associated with attention and memory in addition to the retina. Take this as a real but early signal in older adults, not a settled mainstream claim.
Where the evidence does NOT support strong claims: AREDS2 did not show clear cataract prevention (despite earlier observational hints), there is no all-cause mortality benefit, and there is no good evidence for supplementation in young healthy adults as AMD prevention. The "screen-time supplement" framing has the most data in adults already experiencing visual symptoms from heavy screen use, not as routine prophylaxis.
Practical bottom line: 10mg lutein + 2mg zeaxanthin daily is the trial-validated dose. People with intermediate AMD or a family history should look for the full AREDS2 formula (PreserVision is the market-leading SKU and was the formulation used in the trial). People targeting screen-related eye strain or contrast/glare performance can use either AREDS2-dose products or higher-dose Lutemax 2020 formulations; expect 3-6 months before seeing changes. FloraGLO and Lutemax 2020 are the two standardized forms with their own trial portfolios; generic lutein is the same molecule but quality varies more.
Does It Work? The Evidence
How A-F grades workReduced progression to advanced AMD in higher-risk older adults
Chew 2014 AREDS2 Report No. 3 (PMID 24310343, n=4,203): lutein/zeaxanthin showed an 18% relative risk reduction vs beta-carotene for late AMD; Chew 2022 10-year follow-up (PMID 35653117): 9% reduction in late AMD progression with L/Z, 15% advantage over beta-carotene
Increased macular pigment optical density (MPOD)
Stringham 2016 (PMID 27857944, n=59, 10-20mg lutein + 2-4mg total zeaxanthin x 12 months): significant MPOD increases at 6 and 12 months in both supplementation arms; replicated across dozens of smaller trials
Disability glare, photostress recovery, and contrast sensitivity in healthy adults
Stringham 2016 (PMID 27857944, n=59, 12 months): improved disability glare thresholds and photostress recovery times; Bovier 2014 (PMID 25251377, n=92): ~12% increase in critical flicker fusion thresholds and ~10% faster visual motor reaction time
Visual performance and symptoms in heavy screen users
Stringham 2017 (PMID 28661438, n=48, 24mg/day macular carotenoids x 6 months): significant improvements in MPOD, sleep quality, eye strain, and headache frequency vs placebo in subjects with 6+ hours daily screen exposure
Cognitive function in older adults (attention, processing speed)
Hammond 2017 RCT (PMID 28824416, n=51, 12mg lutein + 2mg zeaxanthin x 12 months): significant improvements in complex attention and cognitive flexibility; Lindbergh 2017 fMRI sub-analysis: improved brain activation on attention tasks in the same cohort
Overall AMD progression in primary AREDS2 analysis (vs placebo)
Age-Related Eye Disease Study 2 Research Group 2013 (PMID 23644932, n=4,203): adding lutein/zeaxanthin to AREDS did NOT significantly reduce overall progression to advanced AMD vs placebo; benefit was confined to subgroups (low dietary L/Z, beta-carotene replacement)
Cataract prevention
AREDS2 did not demonstrate significant cataract progression benefit; observational data (Nurses' Health Study, AREDS observational) suggest associations but no causal RCT evidence
AMD prevention in low-risk or young healthy adults
No RCT has tested primary prevention in low-risk populations; AREDS2 enrolled adults at intermediate or high AMD risk only
| Grade | Claimed Benefit | Key Studies | Our Verdict |
|---|---|---|---|
| A | Reduced progression to advanced AMD in higher-risk older adults | Chew 2014 AREDS2 Report No. 3 (PMID 24310343, n=4,203): lutein/zeaxanthin showed an 18% relative risk reduction vs beta-carotene for late AMD; Chew 2022 10-year follow-up (PMID 35653117): 9% reduction in late AMD progression with L/Z, 15% advantage over beta-carotene | Supported |
| A | Increased macular pigment optical density (MPOD) | Stringham 2016 (PMID 27857944, n=59, 10-20mg lutein + 2-4mg total zeaxanthin x 12 months): significant MPOD increases at 6 and 12 months in both supplementation arms; replicated across dozens of smaller trials | Supported |
| B | Disability glare, photostress recovery, and contrast sensitivity in healthy adults | Stringham 2016 (PMID 27857944, n=59, 12 months): improved disability glare thresholds and photostress recovery times; Bovier 2014 (PMID 25251377, n=92): ~12% increase in critical flicker fusion thresholds and ~10% faster visual motor reaction time | Supported |
| B | Visual performance and symptoms in heavy screen users | Stringham 2017 (PMID 28661438, n=48, 24mg/day macular carotenoids x 6 months): significant improvements in MPOD, sleep quality, eye strain, and headache frequency vs placebo in subjects with 6+ hours daily screen exposure | Early Signal |
| B | Cognitive function in older adults (attention, processing speed) | Hammond 2017 RCT (PMID 28824416, n=51, 12mg lutein + 2mg zeaxanthin x 12 months): significant improvements in complex attention and cognitive flexibility; Lindbergh 2017 fMRI sub-analysis: improved brain activation on attention tasks in the same cohort | Early Signal |
| A | Overall AMD progression in primary AREDS2 analysis (vs placebo) | Age-Related Eye Disease Study 2 Research Group 2013 (PMID 23644932, n=4,203): adding lutein/zeaxanthin to AREDS did NOT significantly reduce overall progression to advanced AMD vs placebo; benefit was confined to subgroups (low dietary L/Z, beta-carotene replacement) | Conflicted |
| C | Cataract prevention | AREDS2 did not demonstrate significant cataract progression benefit; observational data (Nurses' Health Study, AREDS observational) suggest associations but no causal RCT evidence | Conflicted |
| C | AMD prevention in low-risk or young healthy adults | No RCT has tested primary prevention in low-risk populations; AREDS2 enrolled adults at intermediate or high AMD risk only | Not There Yet |
How to Choose: Forms, Doses & What Matters
Clinical dose: 10mg lutein + 2mg zeaxanthin daily (AREDS2 dose); 20mg lutein + 4mg total zeaxanthin in some contrast-sensitivity trials; 10-12mg lutein + 2mg zeaxanthin in cognition trials
Best forms: FloraGLO Lutein (Kemin) - free lutein, the form used in AREDS2 and most positive RCTs; the dominant clinical-grade ingredient on the US market, Lutemax 2020 (OmniActive) - lutein + RR/RS-zeaxanthin + meso-zeaxanthin in a 5:1 ratio; growing trial support, particularly for screen-time/contrast outcomes, Generic lutein / unbranded standardized lutein - same molecule but variable purity, dose accuracy, and bioavailability; reasonable if the brand publishes a third-party CoA
Take with a fat-containing meal. Lutein and zeaxanthin are fat-soluble and absorption can drop by 50% or more when taken on an empty stomach. The AREDS2 dose is 10mg lutein + 2mg zeaxanthin once daily; trial doses for contrast/glare and cognition have ranged up to 20mg lutein + 4mg zeaxanthin daily without safety concerns. Effects on macular pigment density build slowly over 3-6 months; visual performance and cognitive effects in trials read out at 6-12 months. For AMD risk reduction, the AREDS2 full formula (lutein + zeaxanthin + vitamins C and E + zinc + copper) is what was actually tested - PreserVision AREDS2 is the original-formulation SKU. For non-AMD users targeting screen-time, glare, or cognition, a standalone lutein/zeaxanthin product is sufficient.
Who Should Take Lutein + Zeaxanthin?
Adults with intermediate AMD, large drusen, or first-degree relatives with advanced AMD (the populations AREDS2 was powered to detect benefit in). Adults 50+ with low dietary intake of lutein-rich foods (kale, spinach, egg yolks, corn). Heavy screen users experiencing eye strain, glare sensitivity, or slow recovery from bright light exposure. Older adults wanting a modest but evidence-backed cognitive support, particularly for attention and processing speed. Anyone replacing a beta-carotene-containing eye supplement, since lutein/zeaxanthin is the recommended substitute (especially in former smokers, where beta-carotene raises lung cancer risk).
Who Should Avoid It?
Not for everyone
Side Effects & Safety
Product Scores
8 products scored on dosing accuracy, third-party testing, cost per effective dose, and label transparency.
The Scorecard: 8 Products Compared
PreserVision AREDS 2 Formula Eye Vitamin & Mineral Supplement, 120 Softgels
Bausch + Lomb
$35.99 ÷ 120 days at ~5mg/day (0.5 servings × 10mg)
If you're targeting AMD risk reduction specifically, this is the product that was actually studied in AREDS2. For non-AMD goals (screen time, cognition), a standalone lutein/zeaxanthin product is usually a better fit.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
MacuGuard Ocular Support with Saffron, 60 Softgels
Life Extension$24.00 ÷ 60 days at 10mg/day (1 serving × 10mg)
Reasonable middle-ground product for people who want FloraGLO at the trial dose plus meso-zeaxanthin, without the full AREDS2 mineral package.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
EyePromise Restore (Lutemax 2020), 60 Softgels
EyePromise
$49.95 ÷ 60 days at 14mg/day (1 serving × 14mg)
EyePromise has historically been sold through eye-care providers; the same Lutemax 2020 standardized blend is available at lower cost from other brands.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
Lutein & Zeaxanthin (FloraGLO), 60 Softgels
NOW Foods$16.99 ÷ 61 days at 30mg/day (1 serving × 30mg)
NOW's combination of genuine FloraGLO, published CoAs, and a per-mg cost well below the eye-care-channel brands makes this one of the strongest value picks. Good fit for visual performance / screen time goals; less ideal if you specifically want the AREDS2 dose.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
Macular Support Formula, 60 Capsules
Pure Encapsulations$38.50 ÷ 60 days at 10mg/day (1 serving × 10mg)
Best fit if you already buy Pure Encapsulations for other supplements and want consistency in third-party testing standards. For a pure value play on the AREDS2 dose, the NOW or Life Extension SKUs offer a similar carotenoid profile at a lower cost.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
MacuHealth Triple Carotenoid Formula, 90 Softgels
MacuHealth
$99.95 ÷ 90 days at 22mg/day (1 serving × 22mg)
MacuHealth is the dominant US brand of the triple-carotenoid (with meso-zeaxanthin) approach. The MOST trial showed MPOD increases beyond what L/Z alone produces; whether that translates to clinically meaningful visual outcomes over L/Z alone is still being studied.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
Lutein with FloraGLO, 20mg, 60 Veggie Caps
Doctor's Best$14.99 ÷ 60 days at 20mg/day (1 serving × 20mg)
Solid choice for the higher-dose contrast sensitivity range if you don't need the full AREDS2 ratio.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
Lutein 20mg with FloraGLO, 60 Softgels
Jarrow Formulas$17.99 ÷ 60 days at 20mg/day (1 serving × 20mg)
Lutein-heavy formulation. Good if you specifically want a higher single-dose lutein and are getting zeaxanthin from diet or another source.
Prices checked 2026-05-15. Cost shown is per clinically effective daily dose, not per pill.
Full Comparison
| Category | PreserVision AREDS 2 Formula Eye Vitamin & Mineral Supplement, 120 Softgels Bausch + Lomb | MacuGuard Ocular Support with Saffron, 60 Softgels Life Extension | EyePromise Restore (Lutemax 2020), 60 Softgels EyePromise | Lutein & Zeaxanthin (FloraGLO), 60 Softgels NOW Foods | Macular Support Formula, 60 Capsules Pure Encapsulations | MacuHealth Triple Carotenoid Formula, 90 Softgels MacuHealth | Lutein with FloraGLO, 20mg, 60 Veggie Caps Doctor's Best | Lutein 20mg with FloraGLO, 60 Softgels Jarrow Formulas |
|---|---|---|---|---|---|---|---|---|
| Brand Score | 92/100Winner | 86/100 | 86/100 | 84/100 | 84/100 | 84/100 | 82/100 | 81/100 |
| Dosing & Form | 25/25Winner | 23/25 | 24/25 | 23/25 | 23/25 | 24/25 | 22/25 | 22/25 |
| Purity | 21/25Winner | 20/25 | 20/25 | 19/25 | 21/25 | 19/25 | 18/25 | 18/25 |
| Value | 22/25 | 21/25 | 18/25 | 23/25Winner | 17/25 | 17/25 | 23/25 | 22/25 |
| Transparency | 24/25Winner | 22/25 | 24/25 | 19/25 | 23/25 | 24/25 | 19/25 | 19/25 |
| Cost/Day | $0.30 | $0.40 | $0.83 | $0.28 | $0.64 | $1.11 | $0.25Winner | $0.30 |
| Dose/Serving | 10mg | 10mg | 14mg | 30mg | 10mg | 22mg | 20mg | 20mg |
| Form | Softgel (AREDS2 full formula: lutein, zeaxanthin, vitamin C, vitamin E, zinc, copper) | Softgel (FloraGLO lutein + zeaxanthin + meso-zeaxanthin + saffron extract) | Lutemax 2020 softgel (Lutein + RR/RS-zeaxanthin + meso-zeaxanthin) | Softgel (FloraGLO lutein + zeaxanthin) | Capsule (FloraGLO lutein + zeaxanthin + supporting eye-health ingredients) | Softgel (lutein + zeaxanthin + meso-zeaxanthin) | Vegetarian capsule (FloraGLO lutein + zeaxanthin) | Softgel (FloraGLO lutein + zeaxanthin) |
| Third-Party Tested | No | ✓ Yes | No | ✓ Yes | ✓ Yes | No | ✓ Yes | No |
| Proprietary Blend | No | No | No | No | No | No | No | No |
Frequently Asked Questions
Does lutein actually help with screen time and eye strain?
There is more real RCT data here than most 'blue light' marketing implies. The Stringham 2017 Foods study (PMID 28661438) randomized heavy screen users (6+ hours daily) to 24mg/day macular carotenoids vs placebo for 6 months and found significant improvements in macular pigment density, sleep quality, eye strain, and headache frequency. Bovier 2014 (PMID 25251377) showed improvements in visual reaction time and critical flicker fusion in young healthy subjects. The effect is modest and takes months to build, but it is more substantive than typical 'screen time supplement' claims. Lutein does NOT block blue light at the eye-protection level marketed - the mechanism is increased macular pigment density, which improves visual processing under high-contrast and bright-light conditions.
What is the AREDS2 dose, and should I take a higher-dose product?
AREDS2 used 10mg lutein + 2mg zeaxanthin daily, and that is the dose validated for slowing progression to advanced AMD. Some contrast sensitivity and cognition trials have used 12-24mg/day combined macular carotenoids, and Lutemax 2020 products are typically dosed at 20mg lutein + 4mg total zeaxanthin (including meso-zeaxanthin). Higher doses appear safe and may produce slightly larger MPOD increases, but no trial has shown that higher doses improve AMD outcomes beyond the AREDS2 dose. If your goal is AMD risk reduction, 10mg/2mg is the trial-validated answer. If your goal is screen-time/contrast performance, 20mg lutein + 4mg total zeaxanthin (the Stringham 2016 high-dose arm) is the better-studied range.
FloraGLO vs Lutemax 2020 - which is better?
Both are clinically-studied, standardized macular carotenoid ingredients, but the trials differ. FloraGLO (Kemin, free lutein form) is the ingredient used in AREDS2 itself and most of the long-running AMD trials - if you want the form with the strongest macular degeneration evidence, that is FloraGLO. Lutemax 2020 (OmniActive) is a lutein + RR/RS-zeaxanthin + meso-zeaxanthin blend in a 5:1 lutein-to-total-zeaxanthin ratio; it has its own trial portfolio centered on contrast sensitivity, glare, and cognitive function, including the Stringham 2016 and Stringham 2017 studies. Practical: for AMD, FloraGLO. For visual performance and cognition in non-AMD adults, either is defensible. Both have decades of safety data.
Should young healthy adults take lutein/zeaxanthin?
Honest answer: the AMD prevention evidence is in adults already at higher risk (intermediate AMD, large drusen, family history). There is no RCT evidence that supplementation in young healthy adults prevents future AMD. The visual performance and contrast sensitivity data DO extend to young healthy adults (Bovier 2014 used subjects 18-25), so if your goal is glare recovery, contrast under bright light, or screen-time eye strain, there is some signal. If your goal is general 'eye health insurance' in your 20s or 30s, eating lutein-rich foods (kale, spinach, egg yolks) is probably a higher-yield intervention than supplementation.
Should I take lutein/zeaxanthin with food?
Yes. Lutein and zeaxanthin are fat-soluble carotenoids and absorption can drop substantially (some estimates suggest by 50% or more) when taken on an empty stomach. Take with a meal that contains some fat - avocado, olive oil, eggs, fatty fish, or even a small handful of nuts will do. This is also why eating spinach with olive oil produces better bioavailability than spinach alone.
What are the side effects of lutein and zeaxanthin?
Extremely well-tolerated. AREDS2 followed 4,203 participants for 5 years on 10mg/2mg daily with no serious safety signals. The only commonly reported issue is carotenodermia (benign yellow-orange skin discoloration) at very high doses, typically 40mg+ daily and especially in people who also eat very high carotenoid diets. It fades when supplementation stops. No clinically significant drug interactions documented at trial doses. People with fat malabsorption (cystic fibrosis, post-bariatric surgery) may have reduced absorption and should consult their physician.
Will lutein/zeaxanthin reverse macular degeneration or restore lost vision?
No. AREDS2 was specifically designed to test whether supplementation could SLOW progression in people who already had intermediate AMD or other risk factors - and the benefit, where it exists, is a relative risk reduction of about 9-18% in late AMD progression over 5-10 years. It does not restore photoreceptors that have already been damaged, does not reverse geographic atrophy, and is not a substitute for anti-VEGF injections in neovascular AMD. The realistic frame is 'modest reduction in the rate of getting worse,' not 'getting better.'
Sources
- Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015.
- Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132(2):142-149.
- Chew EY, Clemons TE, Agron E, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140(7):692-698.
- Stringham JM, O'Brien KJ, Stringham NT. Macular carotenoid supplementation improves disability glare performance and dynamics of photostress recovery. Eye Vis (Lond). 2016;3:30.
- Stringham JM, Stringham NT, O'Brien KJ. Macular carotenoid supplementation improves visual performance, sleep quality, and adverse physical symptoms in those with high screen time exposure. Foods. 2017;6(7):47.
- Bovier ER, Renzi LM, Hammond BR. A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency. PLoS One. 2014;9(9):e108178.
- Hammond BR Jr, Miller LS, Bello MO, Lindbergh CA, Mewborn C, Renzi-Hammond LM. Effects of lutein/zeaxanthin supplementation on the cognitive function of community dwelling older adults: a randomized, double-masked, placebo-controlled trial. Front Aging Neurosci. 2017;9:254.
- Lindbergh CA, Renzi-Hammond LM, Hammond BR, Terry DP, Mewborn CM, Puente AN, Miller LS. Lutein and zeaxanthin influence brain function in older adults: a randomized controlled trial. J Int Neuropsychol Soc. 2017;23(7):554-566. (DOI: 10.1017/S1355617717000534)
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products discussed on this page are not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any supplement regimen.